Allergan plc (AGN) Stake Lifted by APG Asset Management N.V.

APG Asset Management N.V. lifted its stake in shares of Allergan plc (NYSE:AGN) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 139,347 shares of the company’s stock after acquiring an additional 3,638 shares during the period. APG Asset Management N.V.’s holdings in Allergan were worth $18,983,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in AGN. Cable Hill Partners LLC lifted its holdings in shares of Allergan by 255.2% during the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after acquiring an additional 370 shares during the period. Rockefeller Financial Services Inc. lifted its holdings in shares of Allergan by 283.7% during the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after acquiring an additional 400 shares during the period. Massey Quick & Co. LLC lifted its holdings in shares of Allergan by 334.8% during the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after acquiring an additional 385 shares during the period. Pacific Center for Financial Services lifted its holdings in shares of Allergan by 1.3% during the 2nd quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after acquiring an additional 7 shares during the period. Finally, BB&T Investment Services Inc. lifted its holdings in shares of Allergan by 1,308.2% during the 3rd quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock worth $139,000 after acquiring an additional 641 shares during the period. Institutional investors and hedge funds own 81.21% of the company’s stock.

Allergan plc (AGN) opened at $184.38 on Wednesday. Allergan plc has a 1-year low of $160.07 and a 1-year high of $256.80. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08. The company has a market cap of $62,292.82, a P/E ratio of 12.15, a P/E/G ratio of 1.38 and a beta of 1.11.

Allergan (NYSE:AGN) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.06 by $0.09. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The company had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter last year, the company earned $3.32 earnings per share. Allergan’s revenue for the quarter was up 11.4% on a year-over-year basis. equities analysts expect that Allergan plc will post 16.27 EPS for the current fiscal year.

In other news, Director Chris W. Bodine acquired 3,030 shares of the stock in a transaction on Thursday, December 7th. The stock was bought at an average price of $164.77 per share, with a total value of $499,253.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider William Meury sold 11,807 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. Insiders acquired 17,630 shares of company stock valued at $2,890,057 in the last ninety days. 0.36% of the stock is owned by corporate insiders.

AGN has been the topic of several recent analyst reports. Deutsche Bank set a $251.00 price objective on shares of Allergan and gave the stock a “buy” rating in a report on Tuesday, October 17th. UBS Group set a $255.00 price target on shares of Allergan and gave the company a “buy” rating in a report on Tuesday, October 17th. Cowen restated a “buy” rating on shares of Allergan in a report on Thursday, October 12th. JPMorgan Chase & Co. restated a “buy” rating and issued a $275.00 price target on shares of Allergan in a report on Monday, October 16th. Finally, Wells Fargo & Co set a $276.00 price target on shares of Allergan and gave the company a “buy” rating in a report on Friday, October 13th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $227.56.

WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.com-unik.info/2018/01/31/allergan-plc-agn-stake-lifted-by-apg-asset-management-n-v.html.

Allergan Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit